Parry Romberg Syndrome (PRS) Market
Number of pages: 100 | Report Format: PDF | Published date: March 01, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
CAGR |
3.5% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Diagnosis & Treatment, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Parry-Romberg syndrome market is expected to register a revenue CAGR of 3.5% during the forecast period 2022 to 2030.
Parry Romberg Syndrome (PRS) Market Fundamentals
Parry-Romberg syndrome (PRS) is a rare condition characterized by the gradual degradation (atrophy) of the skin and soft tissues of half of the face (hemifacial atrophy), most commonly the left side. Females are more likely to be affected by this condition than males. The tissues above the top jaw (maxilla) or between the nose and the upper corner of the lip (nasolabial fold) are usually the first to change, followed by the angle of the mouth, areas surrounding the eye, brow, ear, and neck. The tongue, the soft and fleshy region of the roof of the mouth, and the gums may also suffer from degeneration. The affected side’s eye and cheek get sunken, and facial hair turn white and fall out (alopecia). Furthermore, the skin overlaying afflicted areas become darkly pigmented (hyperpigmented), with areas of hyperpigmentation and patches of unpigmented skin appearing in certain situations (vitiligo). PRS is also characterized by neurological abnormalities, such as seizures and severe facial pain episodes (trigeminal neuralgia). The condition commonly appears between the ages of 5 and 15 years.
PRS usually manifests itself within the first or early second decade of life. The most prevalent neurological symptoms in this patient group are migraines and facial discomfort, such as trigeminal neuralgia. Sometimes people develop epilepsy, which is directly related to a brain abnormality ipsilateral to the skin lesion. Only magnetic resonance imaging (MRI) may reveal this as a lesion in the underlying grey or white matter. Moreover, in certain research, the incidence of PRS has been reported to be one in 700,000 people. The etiology of PRS is uncertain and appears to be heterogeneous. Trauma, infection by slow viruses or bacteria, cerebral vascular malformation, immune-mediated process, lipid metabolic problems, and sympathetic dysfunction have all been cited as causes. The pathogenesis is yet unknown. The most common symptom is deformities in the upper face. Neurological and ophthalmological symptoms are also systemic.
Parry Romberg Syndrome (PRS) Market Dynamics
The Parry-Romberg Syndrome market is expected to grow at a rapid pace during the projected period, owing to an increase in the cases of venous disorders and a rise in product approvals to meet this need. Growth in disease awareness, increase in the necessity of early diagnosis, and rise in spending on chronic diseases are expected to drive market expansion. Furthermore, the market’s key players are increasing spending on research and development of technologically enhanced products, resulting in greater utilization of PRS products in both developed and developing countries. Additionally, according to the Centers for Disease Control and Prevention, skin diseases are most common in the United States, with over 7% of skin-related diseases recorded by skin cancer registries, fueling market revenue growth.
According to the World Health Organization, or WHO, neurological anomalies or disorders impact millions of individuals globally. Every year, more than 6 million individuals die as a result of a stroke; more than 80% of these deaths occur in low- and middle-income nations, boosting market revenue growth in developing countries. On the other hand, the high expense of present treatment procedures and the long time for a total cure, for instance, it may take around one to two years for face growth and then surgery, may hinder market expansion.
Parry Romberg Syndrome (PRS) Market Ecosystem
The global Parry-Romberg Syndrome market has been analyzed from three perspectives: diagnosis and treatment, end user, and region.
Parry Romberg Syndrome Market by Diagnosis and Treatment
[8567556]
Based on the diagnosis and treatment, the global Parry-Romberg syndrome market has been segmented into physical examination, MRI scan, serum test, and others. The treatment segment has been sub-segmented into surgery and drugs. The drugs are further sub-segmented into methotrexate, corticosteroids, cyclophosphamide, and azathioprine.
The MRI scan segment dominated the market in 2021. MRI enables improved characterization of soft tissue and bone alterations. MRI brain scans show abnormalities in 10%-20% of people with PRS. These alterations include brain atrophy on the same side as facial abnormalities, as well as inflammation within the brain. MRI is most commonly used to diagnose neurological problems. Females are more likely to suffer from PRS than males.
Fat or silicone injections, flap/pedicle grafts, or bone implants are some of the surgical methods utilized to treat people with PRS. These surgeries may help with cosmetic enhancement. However, fat injections may be reabsorbed if given during the active disease phase.
A flap/pedicle technique is a skin and tissue graft that is left temporarily linked to its original site in order to ensure a steady blood supply while it heals into place. A range of surgical methods have been utilized to improve affected people’s cosmetic appearance. The success rates of these surgical treatments vary greatly. Surgical treatment is usually not recommended until the atrophic alterations have stopped and the extent of the ensuing facial deformities has been determined. Some doctors urge people with PRS to postpone any surgical operations for at least a year, until the skull and face have fully matured, and the symptoms have dissipated. Methotrexate, corticosteroids, mycophenolate mofetil, cyclosporine, azathioprine, and hydroxychloroquine have also been used with mixed results. These terms have been used since it is believed that Parry Romberg Syndrome is an autoimmune disorder that overlaps with inflammatory conditions, such as scleroderma. Further research is needed to assess the long-term safety and efficacy of immunosuppressive medications in the treatment of PRS. Moreover, immunosuppressive medicines may help some individuals control their seizures, especially if they have PRS and linear scleroderma.
Parry Romberg Syndrome Market by End User
Based on the end user, the global Parry-Romberg syndrome market has been segmented into hospitals & clinics, physical therapists, and others.
The hospitals & clinics segment is expected to dominate the market during the forecast period. Hospitals and clinics offer dedicated and skilled teams of specialists from many disciplines that provide the care and expertise required to treat this rare and complex ailment for parents and children. Surgeons discuss particular treatment choices with the child in order to personalize the treatment. Because each patient’s needs are unique, the surgical strategy used to treat each child’s disease may differ dramatically.
Parry Romberg Syndrome Market by Region
Based on the region, the global Parry-Romberg syndrome market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America dominates the global Parry-Romberg syndrome market due to the presence of a large older population and increase in the number of patients with neurological disorders and eye-related ailments. Furthermore, rapid healthcare delivery, advanced hospital infrastructure, and the availability of skilled healthcare professionals are driving market expansion in North America.
The market in Europe is expected to register growth at significant revenue CAGR during the forecast period due to rise in government funding for research and development and increase in expenditure in healthcare. Countries such as France and Germany are investing in healthcare research to develop breakthrough diagnostic and treatment approaches for rare diseases, which is expected to boost market revenue growth.
Asia Pacific is the fastest growing market, owing to increasing government support for research and development, rising prevalence of skin and eye illnesses, a large population base, and rapidly developing economies in the region. Several regional developing countries, such as India, are concentrating their efforts on the expansion of the healthcare industry, fueling market development.
Parry Romberg Syndrome (PRS) Market Competitive Landscape
The companies operating in the market are capitalizing on the healthcare business segment to maintain their market leadership. Companies are leveraging extensive R&D platforms based on drug discovery, preclinical research, clinical trials, and manufacturing technologies. Focused R&D activities are leading to the successful development of product candidates and potential revenue growth. Commercialization of a broad product pipeline is also offering significant revenue-generating opportunities to companies. Besides, the market expansion is also likely to be driven by advancements in treatment methods. Numerous initiatives by government and non-profit organizations to provide funding for rare diseases, including PRS, and spreading illness awareness among healthcare professionals and patients are propelling market expansion.
The prominent players in the global Parry-Romberg syndrome market include:
Europe is a key revenue growth region in the global Parry-Romberg syndrome market.
The increasing incidence of rare diseases, as well as the prevalence of autoimmune, are the prime factors driving market development.
The Parry-Romberg syndrome market is expected to register a revenue CAGR of 3.5% during the forecast period.
Some of the prominent players in the global Parry-Romberg syndrome market include DePuy Synthes, Johnson & Johnson Services, Inc., and Medtronic Plc.
The MRI scan segment leads the global Parry-Romberg syndrome market.
*Insights on financial performance are subject to the availability of information in the public domain